| |
| |
|
| Insider
Information: |
Epperly Melissa B, |
| Relationship: |
|
| City: |
New York |
| State: |
NY |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
474,010 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$256,744 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
474,010 |
|
|
| Total
Value |
$256,744 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
|
|
| Stock
price went down : |
|
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Zentalis Pharmaceuticals, Llc |
ZNTL |
Chief Financial Officer |
2024-02-12 |
451,449 |
|
0 |
Premium* |
|
|
Roivant Sciences Ltd. |
ROIV |
|
2024-04-24 |
22,561 |
2023-07-03 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ROIV |
Roivant Sciences Ltd. |
|
• • – |
2024-04-24 |
4 |
D |
$10.90 |
$1,341 |
D/D |
(123) |
22,561 |
0 |
- |
|
| ROIV |
Roivant Sciences Ltd. |
|
• • – |
2024-04-24 |
4 |
A |
$0.00 |
$0 |
D/D |
1,146 |
22,684 |
0 |
- |
|
| ZNTL |
Zentalis Pharmaceuticals,... |
Chief Financial Officer |
• – – |
2024-02-12 |
4 |
AS |
$11.44 |
$29,435 |
D/D |
(2,573) |
451,449 |
0 |
- |
|
| ZNTL |
Zentalis Pharmaceuticals,... |
Chief Financial Officer |
• – – |
2024-02-02 |
4 |
AS |
$11.54 |
$100,040 |
D/D |
(8,669) |
454,022 |
0 |
- |
|
| ZNTL |
Zentalis Pharmaceuticals,... |
Chief Financial Officer |
• – – |
2024-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
462,691 |
0 |
- |
|
| ROIV |
Roivant Sciences Ltd. |
|
• • – |
2024-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
1,207 |
21,538 |
0 |
- |
|
| ROIV |
Roivant Sciences Ltd. |
|
• • – |
2023-10-16 |
4 |
A |
$0.00 |
$0 |
D/D |
1,226 |
20,331 |
0 |
- |
|
| ZNTL |
Zentalis Pharmaceuticals,... |
Chief Financial Officer |
• – – |
2023-10-04 |
4 |
AS |
$19.43 |
$106,926 |
D/D |
(5,482) |
387,691 |
0 |
- |
|
| ROIV |
Roivant Sciences Ltd. |
|
• • – |
2023-09-12 |
4 |
A |
$0.00 |
$0 |
D/D |
17,825 |
19,105 |
0 |
- |
|
| ROIV |
Roivant Sciences Ltd. |
|
• • – |
2023-07-03 |
4 |
A |
$0.00 |
$0 |
D/D |
1,280 |
1,280 |
0 |
- |
|
| ZNTL |
Zentalis Pharmaceuticals,... |
Chief Financial Officer |
• – – |
2023-02-14 |
4 |
AS |
$19.98 |
$104,411 |
D/D |
(5,227) |
392,048 |
0 |
- |
|
| ZNTL |
Zentalis Pharmaceuticals,... |
Chief Financial Officer |
• – – |
2023-02-13 |
4 |
AS |
$20.42 |
$53,594 |
D/D |
(2,624) |
397,275 |
0 |
- |
|
| ZNTL |
Zentalis Pharmaceuticals,... |
Chief Financial Officer |
• – – |
2023-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
101,957 |
399,899 |
0 |
- |
|
| ZNTL |
Zentalis Pharmaceuticals,... |
Chief Financial Officer |
• – – |
2022-10-03 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
297,543 |
0 |
- |
|
| ZNTL |
Zentalis Pharmaceuticals,... |
Chief Financial Officer |
• – – |
2022-04-04 |
4 |
AS |
$48.75 |
$855,522 |
D/D |
(17,080) |
247,414 |
0 |
- |
|
| ZNTL |
Zentalis Pharmaceuticals,... |
Chief Financial Officer |
• – – |
2022-02-23 |
4 |
AS |
$48.81 |
$93,921 |
D/D |
(1,913) |
264,494 |
0 |
- |
|
| ZNTL |
Zentalis Pharmaceuticals,... |
Chief Financial Officer |
• – – |
2022-02-10 |
4 |
A |
$0.00 |
$0 |
D/D |
16,405 |
266,407 |
0 |
- |
|
| ZNTL |
Zentalis Pharmaceuticals,... |
Chief Financial Officer |
• – – |
2021-10-02 |
4 |
D |
$67.13 |
$1,146,580 |
D/D |
(17,080) |
250,002 |
0 |
- |
|
| ZNTL |
Zentalis Pharmaceuticals,... |
Chief Financial Officer |
• – – |
2021-08-19 |
4 |
B |
$52.00 |
$430,800 |
D/D |
8,285 |
266,685 |
2.74 |
- |
|
| ZNTL |
Zentalis Pharmaceuticals,... |
Chief Financial Officer |
• – – |
2021-08-18 |
4 |
B |
$52.00 |
$68,948 |
D/D |
1,326 |
258,400 |
2.74 |
- |
|
| ZNTL |
Zentalis Pharmaceuticals,... |
Chief Financial Officer |
• – – |
2021-07-01 |
4 |
AS |
$50.10 |
$158,054 |
D/D |
(3,083) |
257,074 |
0 |
- |
|
| ZNTL |
Zentalis Pharmaceuticals,... |
Chief Financial Officer |
• – – |
2021-06-01 |
4 |
AS |
$53.99 |
$166,641 |
D/D |
(3,083) |
260,157 |
0 |
- |
|
| ZNTL |
Zentalis Pharmaceuticals,... |
Chief Financial Officer |
• – – |
2021-05-03 |
4 |
AS |
$56.99 |
$182,635 |
D/D |
(3,083) |
263,240 |
0 |
- |
|
| ZNTL |
Zentalis Pharmaceuticals,... |
Chief Financial Officer |
• – – |
2021-03-01 |
4 |
AS |
$41.67 |
$128,482 |
D/D |
(3,083) |
283,430 |
0 |
- |
|
| ZNTL |
Zentalis Pharmaceuticals,... |
Chief Financial Officer |
• – – |
2021-02-11 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
286,513 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
